Blood pressure and metabolic effects of acetyl-L-carnitine in type 2 diabetes: DIABASI randomized controlled trial by A. Parvanova et al.
ISSN 2472-1972
Blood Pressure and Metabolic Effects of
Acetyl-L-Carnitine in Type 2 Diabetes:
DIABASIRandomizedControlledTrial
Aneliya Parvanova,1* Matias Trillini,1* Manuel A. Podesta`,1,2* Ilian P. Iliev,1
Carolina Aparicio,1 Annalisa Perna,1 Francesco Peraro,1 Nadia Rubis,1
Flavio Gaspari,1 Antonio Cannata,1 Silvia Ferrari,1 Antonio C. Bossi,3
Roberto Trevisan,4 Sreejith Parameswaran,5 Jonathan S. Cha´vez-I~niguez,6
Fahrudin Masnic,7 Sidy Mohamed Seck,8 Teerayuth Jiamjariyaporn,9
Monica Cortinovis,1 Luca Perico,1 Kanishka Sharma,1 Giuseppe Remuzzi,1,2,10†
Piero Ruggenenti,1,2† and David G. Warnock11†
1IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24126 Bergamo, Italy; 2Department of
Medicine, Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII,
24127 Bergamo, Italy; 3Unit of Diabetology, Azienda Socio-Sanitaria Territoriale Bergamo Ovest, 24047
Treviglio–Caravaggio–Romano, Italy; 4Unit of Diabetology, Azienda Socio-Sanitaria Territoriale Papa
Giovanni XXIII, 24127 Bergamo, Italy; 5Jawaharlal Institute of Postgraduate Medical Education and
Research, 605006 Tamil Nadu, India; 6Hospital Civil de Guadalajara “Fray Antonio Alcalde,” Servicio
de Nefrologı´a, 44281 Guadalajara, Mexico; 7Clinic for Hemodialysis, University Clinical Center
Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina; 8Department of Nephrology, Faculty of Health
Sciences, University Gaston Berger, BP 234 Saint-Louis, Senegal; 9Bhumi Rajanagarindra Kidney
Institute, 10400 Bangkok, Thailand; 10Department of Biomedical and Clinical Science, L. Sacco,
University of Milan, 20157 Milan, Italy; and 11Department of Medicine, University of Alabama at
Birmingham, Birmingham, Alabama 35294
*These authors contributed equally to this study as first authors.
†These authors contributed equally to this study as last authors.
Context: Acetyl-L-carnitine (ALC), a mitochondrial carrier involved in lipid oxidation and glucose
metabolism, decreased systolic blood pressure (SBP), and ameliorated insulin sensitivity in hyper-
tensive nondiabetic subjects at high cardiovascular risk.
Objective: To assess the effects of ALC on SBP and glycemic and lipid control in patients with hy-
pertension, type 2 diabetes mellitus (T2D), and dyslipidemia on background statin therapy.
Design: After 4-week run-in period and stratification according to previous statin therapy, patients
were randomized to 6-month, double-blind treatment with ALC or placebo added-on simvastatin.
Setting: Five diabetology units and one clinical research center in Italy.
Patients: Two hundred twenty-nine patients with hypertension and dyslipidemic T2D.40 years with
stable background antihypertensive, hypoglycemic, and statin therapy and serum creatinine ,1.5 mg/
dL.
Interventions: Oral ALC 1000 mg or placebo twice daily on top of stable simvastatin therapy.
Outcome andMeasures: Primary outcome was SBP. Secondary outcomes included lipid and glycemic
profiles. Total-body glucose disposal rate and glomerular filtration rate were measured in subgroups by
hyperinsulinemic–euglycemic clamp and iohexol plasma clearance, respectively.
Abbreviations: ALC, acetyl-L-carnitine; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; GDR, glucose
disposal rate; GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, ho-
meostatic model assessment of insulin resistance; IQR, interquartile range; LDL, low-density lipoprotein; SD, standard deviation;
SBP, systolic blood pressure; T2D, type 2 diabetes.
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Results: SBP did not significantly change after 6-month treatment with ALC compared with placebo
(22.09mmHg vs23.57mmHg,P = 0.9539). Serum cholesterol, triglycerides, and lipoprotein(a), as well
as blood glucose, glycated hemoglobin, fasting insulin levels, homeostatic model assessment of insulin
resistance index, glucose disposal rate, and glomerular filtration rate did not significantly differ between
treatments. Adverse events were comparable between groups.
Conclusions: Six-month oral ALC supplementation did not affect blood pressure, lipid and glycemic
control, insulin sensitivity and kidney function in hypertensive normoalbuminuric and micro-
albuminuric T2D patients on background statin therapy.
Copyright © 2018 Endocrine Society
Thisarticlehasbeenpublishedunder the termsof theCreativeCommonsAttributionNon-Commercial,
No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Up to 75% of patients with type 2 diabetes mellitus (T2D) worldwide are hypertensive [1].
Arterial hypertension constitutes a major risk factor for cardiovascular disease and a pre-
dictor of microvascular and macrovascular complications in patients with T2D [2]. Blood
pressure (BP) control effectively decreases cardiovascular complications of T2D; however, the
reduction of systolic BP (SBP) to normal range is difficult to achieve despite multidrug
treatments [3, 4]. Additionally, the concomitant diastolic BP (DBP) reduction observed in
patients on antihypertensive medications represents a risk factor for coronary events [5].
Dyslipidemia, another major cardiovascular risk factor, is also frequently observed in
patients with T2D. Statins improve hypercholesterolemia by essentially reducing total and
low-density lipoprotein (LDL) cholesterol fraction levels but they marginally affect tri-
glycerides and lipoprotein(a), both associated with worse cardiovascular outcomes [2, 6].
Thus, novel treatment options to improve the control of hypertension and dyslipidemia in
patients with T2D are needed.
L-Carnitine and its ester acetyl-L-carnitine (ALC) are mitochondrial carriers of acyl and
acetyl groups, both of which are involved in lipid oxidation and glucose metabolism. These
compounds stimulate the activity of the pyruvate dehydrogenase complex and activate the
glycolytic pathway [7]. Additionally, they facilitate mitochondrial uptake of long-chain fatty
acids, leading to improved b-oxidation and thus overcoming the mitochondrial oxidative
phosphorylation defect observed in T2D [8, 9]. Such actions may in turn lead to more efficient
oxidative glucose utilization and storage and counteract the shift in substrate use from
carbohydrates to lipids commonly observed with insulin resistance [10, 11].
Previous studies reported an improvement in insulin sensitivity among patients with T2D
treated with intravenous L-carnitine [12, 13]. In a pilot study, our group found that along with
an improvement in insulin sensitivity, oral ALC also decreased SBPwithout affecting DBP in
nondiabetic subjects at high cardiovascular risk [14]. The significant correlation between SBP
and insulin resistance suggested that BP reduction could be explained, at least in part, by
insulin sensitivity amelioration. This was likely not the only driver of SBP reduction, because
the enhancement of insulin sensitivity was appreciable only in more severely insulin-
resistant subjects, whereas BP was reduced in all subjects regardless of their glucose dis-
posal rate (GDR) at inclusion.
Consistently, evidence from animal models of hypertension suggests that increased car-
nitine activity may be linked to systemic oxidative stress reduction and higher nitric oxide
availability, along with a downregulation of renin–angiotensin–aldosterone system compo-
nents [15, 16]; these data suggest that carnitine could exert a direct effect on the vascular tone
and thus play a role in BP regulation.
Additionally, whereas small pilot studies in patients with T2D showed controversial re-
sults regarding the effects of oral L-carnitine on serum triglycerides and lipoprotein(a)
[17–19], a recent meta-analysis showed that oral L-carnitine had no significant effect on these
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serum lipid components, but produced a significant reduction in total and LDL cholesterol
[20]. Moreover, data from the trials exploring the effect of the combined therapy with
L-carnitine and simvastatin on lipid profile in T2D are encouraging, although not conclusive
[21–23].
Taken together, the evidence suggests that oral ALC might reduce BP and drive positive
effects on the lipid profile in patients with T2D. However, no prospective randomized and
controlled study has tested the efficacy of oral ALConBPand lipidmetabolismwhenadded on
top of statins in this population. Therefore, we aimed to assess the effects of a 6-month therapy
with oral ALC on SBP andmetabolic profile in patients with hypertensive normoalbuminuric
and microalbuminuric T2D with dyslipidemia on stable antihypertensive, hypoglycemic, and
statin therapy.
1. Materials and Methods
A. Patients
In this prospective, randomized, phase III, double-blind, placebo-controlled trial we
screened for eligibility patients from five outpatient clinics of northern Italy (DIABASI
Study Organization, see Appendix 1). Inclusion criteria were T2D (World Health Orga-
nization criteria), age .40 years, arterial hypertension (defined according to the Seventh
Report of the Joint National Committee of Prevention, Detection, Evaluation and
Treatment of High Blood Pressure [24]: SBP $ 140 mm Hg or DBP $ 90 mm Hg and/or
concomitant use of antihypertensive medications), dyslipidemia (based on National
Cholesterol Education Program criteria [25] and/or patients who were already treated
with lipid-lowering drugs), and serum creatinine concentrations ,1.5 mg/dL on stable
background antihypertensive, hypoglycemic, and lipid-lowering therapy. Patients with
uncontrolled T2D (glycosylated hemoglobin . 110 mmol/mol or 12.2%), acute cardio-
vascular events during the last 3 months, history of hypersensitivity to the study drug,
evidence of immunologically mediated renal disease, major systemic diseases, cancer,
drug or alcohol abuse, as well as pregnant, lactating, and potentially childbearing women
without adequate contraception or subjects unable to provide informed consent were
excluded from the study. Every patient provided written informed consent before
enrolment in the study.
B. Study Design and Intervention
After the screening evaluation, potentially eligible patients entered a 4-week run-in period
(Fig. 1). Patients fulfilling selection criteria were also stratified according to previous therapy
with statins (i.e., previous statin therapy YES or NO). Patients already receiving statin
therapy were maintained on an equivalent dose of simvastatin (10 to 20mg/d) up to the study
end, whereas patients who were not on statin therapy started simvastatin 10 or 20 mg/d as
deemed clinically appropriate. A safety visit was performed 10 days after the screening visit.
At the end of the 4-week run-in period, baseline evaluation of demographic characteristics,
vital parameters, and laboratory analyses were performed. Within each stratum (i.e., pre-
vious statin therapy YES or NO), patients were randomly allocated on a 1:1 basis to 6-month
treatment with oral ALC (1000 mg twice each day) or placebo.
Computer-generated randomization was centralized at the Laboratory of Biostatistics of
the coordinating center under the responsibility of an independent investigator. Randomi-
zation was stratified in blocks by center, with block size randomly varying to increase the
unpredictability of the sequence. Patients received treatment boxes with a unique tag rep-
resenting the randomly allocated study sequence. Placebo capsules were identical to ALC
capsules in shape, smell, and taste. Patients, investigators, and all of the personnel involved
in the study were blinded to treatment allocation whereas information regarding previous
statin therapy and simvastatin dose during the run-in and the study treatment periods
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remained unmasked. Study drug supplywas performed at baseline visit and after 3months of
treatment. Clinical assessments and laboratory analyses were performed 3 and 6 months
after randomization along with assessment of patient compliance to study drug and rec-
ommendations concerning physical activity and diet. At baseline and at final visits GDR and
glomerular filtration rate (GFR) were evaluated in subgroups including the first 50 and 74
consenting patients, respectively. All patients were recommended to adhere to Italian As-
sociation of Diabetologists–Italian Society of Diabetology guidelines on diet and physical
activity [26]. However, no substantial changes in diet, physical activity, or concomitant
treatments were allowed throughout the study period to prevent confounding the study
findings.
The study was carried out in accordance with the Declaration of Helsinki, and the clinical
trial protocol was approved by the Ethics Committee of every participating center. The
Clinical Research Center for Rare Diseases “Aldo e Cele Dacco`” of the IRCCS Mario Negri
Institute for Pharmacological Research (Ranica, Italy) coordinated and monitored the study
and processed all laboratory samples. This study is registered on ClinicalTrial.gov
(NCT00984750) and ClinicalTrialsRegister.eu (EUDRACT 2007-005925-31).
C. Outcomes
The primary outcome was the change in SBP after 6-month treatment with ALC compared
with placebo. Secondary outcomes included changes in DBP, lipid and glycemic profile, in-
sulin sensitivity, urinary albumin excretion, and GFR after ALC treatment compared with
placebo.
Figure 1. Study design.
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D. Measurements
Office SBP and DBP were measured in the morning before treatment by means of an ap-
propriate cuff, with the same sphygmomanometer (Omron 705IT; Omron, Hoofddorp,
Netherlands) andwith the patient in a sitting position after$5minutes of rest. The average of
three measurements taken 2 minutes apart was recorded for statistical analyses. Twenty-
four–hour ambulatory BP was monitored and recorded in a representative subgroup of
consenting patients by TM-2430 equipment (A&D Company, Tokyo, Japan) that was set
to obtain measurements at 15-minute intervals during daytime (6:00 AM to 10:00 PM) and
30-minute intervals during nighttime (10:00 PM to 6:00 AM).
Blood was sampled the morning after overnight fasting for laboratory assessments. The
patients were advised to maintain usual habits and to avoid physically intense/vigorous
exercise, smoking, or substantial changes in regular diet the day before the examination. For
the night before testing they were instructed to consume a low-carbohydrate meal and to
avoid alcohol consumption. Eating after midnight was forbidden. The patients were allowed
to drink water in the morning.
Insulin sensitivity was assessed by total GDR measured during the hyperinsulinemic–
euglycemic clamp in a subgroup of 50 patients [27] and by homeostatic model assessment in
all patients [28].
For the hyperinsulinemic–euglycemic clamp, insulin was infused at a constant rate of
4 mU/kg/min for 10 minutes and then decreased to 2 mU/kg/min. This infusion rate was
maintained throughout the duration of the procedure. As soon as the blood glucose con-
centration decreased to 90 6 5 mg/dL, the hyperinsulinemic–euglycemic clamp was started
(time 0). From time 0, the blood glucose concentration was assayed with the glucose-oxidized
method every 5 minutes and it was maintained at this level (90 6 5 mg/dL) for 2 hours by a
variable rate of 20% glucose solution infusion through an automated pump. During the last
30 minutes of the clamp, three blood samples were collected every 10 minutes for insulin
measurements to confirm a steady-state plasma insulin concentration. Because at the
achieved plasma insulin concentration the hepatic glucose production should be suppressed,
the amount of glucose required to maintain steady-state euglycemia was assumed to be equal
to the total-body glucose disposal. Thus, total-body GDR was calculated as the mean of the
glucose infusion rate during the last 30minutes of the clamp and expressed asmilligrams per
kilogram per minute.
The homeostatic model assessment of insulin resistance (HOMA-IR) index was calculated
through the formula:HOMA-IR= [fasting serumglucose (mg/dL)3 fasting insulin (mIU/mL)]/
405. Lipoprotein(a) was measured by nephelometry (Immage; Beckman Coulter). Serum
creatinine, lipid concentrations, and other routine laboratory parameters were assessed by a
Beckman Coulter Synchron CX9 automatic analyzer whereas glycosylated hemoglobin
(HbA1c) was evaluated by high-performance liquid chromatography [normal laboratory
range, 25.0 mmol/mol to 38.9 mmol/mol (International Federation of Clinical Chemistry and
Laboratory Medicine) or 4.4% to 5.7% (Diabetes Control and Complications Trial); Beckman
Coulter System Gold chromatograph].
Albuminuria was measured in three consecutive overnight urine collections by rate
nephelometry (Array 360 system; BeckmanCoulter,Milan, Italy). The sensitivity of the assay
was 2 mg/L.
Glomerular filtration rate wasmeasured by the plasma clearance of unlabeled iohexol [29].
Briefly, on themorning of renal function evaluation, 5mL of iohexol solution (Omnipaque 300;
GE Health Care, Milan, Italy) was injected intravenously during 2 minutes. Blood samples
were then taken before iohexol injection (predose blank sample) and at different time points
after completion of iohexol administration.
E. Sample Size Estimation and Statistical Analysis
On the basis of preliminary data in nondiabetic subjects with insulin resistance [14], SBP in
eligible patients was expected to average 142.2 6 16.3 mm Hg at baseline and decrease by
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10mmHgat study end in those randomized toALC.Assuming a similar SBPat baseline and a
3mmHg reduction at study end in those randomized to placebo, 104 patients per groupwould
have given the trial an 80% power to detect a statistically significant difference (P, 0.05 two-
tailed test) at 6 months. Assuming a 10% dropout rate, 114 patients per group had to be
included to ensure at least 104 patients were available for the final analysis. Accordingly, a
total of 229 patients were included and randomized. In a subgroup of consenting patients
GFR and GDR were also measured. These were secondary, explorative outcome variables,
and the number of patients to evaluate by the iohexol plasma clearance technique and
hyperinsulinemic–euglycemic clamp was not calculated a priori on the basis of an expected
treatment effect, but was dictated by feasibility, considering that both procedures are time-
and cost-consuming and demanding for both patients and investigators.
Continuous variables were reported as mean [standard deviation (SD)] or median
[interquartile range (IQR)], whereas categorical parameters were described by counts and
percentages. Baseline characteristics of the patientswere compared using the x2 test, Fisher’s
exact test, unpaired t test, or Wilcoxon rank-sum test, as appropriate. Statistical analyses
were performed by modified intention to treat, which included all randomized patients who
had received at least one dose of study drug. Within-group treatment effects were assessed
by a paired t test or Wilcoxon signed rank test as appropriate. Between-group comparisons
were carried out by means of analysis of covariance, adjusting for the measurements
at randomization. All the statistical analyses were performed using SAS version 9.1 (SAS
Institute) and STATA version 12. A P value of ,0.05 was considered statistically
significant.
2. Results
A. Patients’ Characteristics
Of 247 participants screened from 26 June 2008 to 31 May 2011, 229 fulfilled the selection
criteria and were randomized (116 patients to ALC and 113 to placebo). Ten of these patients,
seven on ALC and three on placebo, did not complete the study because of consent withdrawal
(n = 5), loss to follow-up (n = 3), an adverse event (n = 1), and protocol violation (n = 1) (Fig. 2).
All patients were white and 72%were males. According to the diagnostic criteria described
in the Seventh Report of the Joint National Committee of Prevention, Detection, Evaluation
and Treatment of High Blood Pressure [24], all of them were hypertensive. Overall, 95% of
patients from both groups were on treatment with one ormore antihypertensivemedications,
whereas the others weremanaged by dietarymodifications alone according to guidelines [26].
SBP as well as other anthropometric, clinical, and laboratory parameters were comparable
between groups at baseline. Although the prevalence of current smokers was higher in
patients randomized to ALC compared with those on placebo, the difference between groups
did not achieve statistical significance. Baseline characteristics of patients according to study
treatment and stratification based on previous statin therapy are shown inTable 1. Of note, at
the beginning of the study, baseline triglycerides and total and LDL cholesterol levels were
higher in subjects who were on long-term statin therapy compared with those on short-term
statin (P , 0.001 for all specified parameters). Baseline distribution of antihypertensive,
hypoglycemic, and lipid-lowering agents was balanced between considered groups and strata
(Table 1). Adherence to study drug was assessed by pill count scheduled at every visit.
Compliance rates in the ALC and the placebo groups were similar and averaged 87%.
B. Effects of ALC vs Placebo
B-1. Blood pressure
SBP was not significantly different after 6 months of treatment with ALC or placebo, even
after adjustment for baseline values (P = 0.9539). However, when compared with baseline,
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SBP did not appreciably change after treatment with ALC whereas it significantly decreased
in patients allocated to placebo (from 138.16 18.3mmHg to 134.56 15.1mmHg; P = 0.0187)
(Table 2).
Similarly, when strata were considered separately (previous statin YES or statin NO, i.e.,
long- and short-term statin), the difference in SBP between ALC and placebo groups was not
statistically significant. However, in the short-term statin therapy, SBP significantly de-
creased only when patients took placebo (137.6 6 17.4 mm Hg to 133.2 6 13.6 mm Hg; P =
0.015) (Table 3).
Overall, the effect of ALC on DBP was not significantly different from that of placebo (P =
0.8994) (Table 2), whereas DBPwas significantly reduced after 6months of ALC (from 79.96
6.7 to 78.46 7.5; P = 0.0387). Irrespective of the stratum considered, ALC and placebo had no
appreciable effects on DBP compared with baseline.
Thirty-eight patients had changes in antihypertensive medications throughout the study
period, of which 20 were on ALC (12 in the long-term statin and 8 in the short-term statin
Figure 2. Flow diagram representing the disposition of subjects.
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Table 1. Baseline Characteristics of Patients Randomized to ALC or Placebo Therapy in the Study
Group Considered as Whole (Overall) or According to Previous Treatment With Statins (YES or NO)
Overall (n = 229)
Previous Statin
Therapy
YES (n = 117)
Previous Statin
Therapy
NO (n = 112)
ALC
(n = 116)
Placebo
(n = 113)
ALC
(n = 61)
Placebo
(n = 56)
ALC
(n = 55)
Placebo
(n = 57)
Demographic
characteristics
Age, y 64.9 6 7.7 64.6 6 7.5 65.4 6 6.9 64.2 6 73 64.4 6 8.6 65.0 6 7.7
Sex, male/female 81/35 84/29 41/20 41/15 40/15 43/14
Smoker, current/former 26/44 15/52 17/22 10/23 9/22 5/29
Weight, kg 83.3 6 14.4 84.4 6 15.3 84.0 6 14.1 87.2 6 17.0 82.6 6 14.8 81.8 6 13.2
BMI, kg/m2 30.0 + 4.7 30.0 + 5.0 30.3 6 4.3 30.9 6 21.1 29.8 6 5.2 29.2 6 4.5
Clinical characteristics
SBP, mm Hg 136.5 6 14.3 138.1 6 18.1 137.4 6 13.6 138.4 6 19.2 135.5 6 15.0 137.8 6 17.2
DBP, mm Hg 79.8 6 6.7 79.0 6 10.2 79.9 6 6.6 78.5 6 10.6 80.7 6 6.8 79.6 6 9.9
Mean BP, mm Hg 98.7 6 7.5 98.7 6 11.1 98.4 6 7.2 98.4 6 11.5 99.0 6 7.9 99.0 6 10.9
Laboratory parameters
Serum glucose, mg/dL 148.2 6 42.0 155.2 6 42.1 150.9 6 45.4 155.1 6 44.6 145.2 6 38.0 155.3 6 40.1
HbA1c, mmol/mol 51.0 6 13.6 51.0 6 13.2 52.7 6 12.6 53.6 6 14.6 49.1 6 14.6 48.4 6 11.3
HbA1c, % 6.8 6 1.24 6.8 6 1.21 7.0 6 1.15 7.1 6 1.34 6.6 6 1.34 6.6 6 1.03
Insulin, mIU/mL 9.0 [6.4–15.1] 9.2 [6.1–14.9] 8.9 [7.3–15.8] 10.5 [6.3–16.9] 9.1 [5.7–14.5] 9.2 [6.1–14.9]
HOMA-IR 3.2 [2.0–5.9] 3.3 [2.1–5.6] 3.3 [2.1–6.1] 4.1 [2.0–6.0] 3.0 [1.8–5.8] 3.0 [2.1–4.7]
GDR, mg/kg/mina 5.6 [4.3–8.4] 5.8 [4.6–7.8] 5.6 [3.9–7.8] 5.6 [4.8–6.3] 5.7 [4.3–8.4] 6.3 [4.2–9.2]
Total cholesterol, mg/dL 158.2 6 30.9 155.2 6 33.7 167.0 6 31.7 170.6 6 35.1 148.5 6 27.1 140.1 6 24.3
HDL cholesterol, mg/dL 44.9 6 13.3 44.8 6 11.9 42.8 6 10.8 45.3 6 12.1 47.2 6 15.4 44.2 6 11.7
LDL cholesterol, mg/dL 93.5 6 26.8 90.9 6 26.6 100.9 6 26.6 103.2 6 27.2 85.4 6 24.8 78.9 6 19.9
Triglycerides, mg/dL 107.0 [83.0–144.5] 107.0 [74.0–148.0] 126.0 [85.0–173.0] 113.0 [84.0–182.0] 98.0 [64.0–124.0] 100.0 [70.0–126.0]
Lipoprotein(a), mIU/mL 9.0 [3.4–34.7] 11.5 [3.6–30.5] 11.3 [4.2–36.0] 16.8 [3.7–34.8] 6.1 [3.1–34.4] 9.3 [3.5–28.4]
Kidney function parameters
Serum creatinine, mg/dL 0.93 6 0.2 0.95 6 0.2 0.92 6 0.2 0.96 6 0.2 0.94 6 0.2 0.93 6 0.2
GFR, mL/min/1.73 m2b 97.1 6 24.4 99.7 6 25.5 99.2 6 19.2 97.8 6 27.8 94.5 6 29.8 101.2 6 24.0
Albuminuria, mg/min 11.9 [3.8–46.4] 10.6 [4.2–44.6] 14.4 [39–43.0] 18.6 [4.4–56.5] 11.7 [3.7–78.8] 7.6 [3.7–31.2]
Patients on pharmacological
medications, n (%)
Antihypertensive agents
Any 110 (95) 107 (95) 58 (95) 54 (96) 52 (95) 53 (93)
Diuretics 73 (63) 60 (53) 41 (67) 28 (50) 32 (58) 32 (56)
Angiotensin-converting
enzyme inhibitors
65 (56) 53 (47) 37 (61) 26 (46) 28 (51) 27 (47)
Angiotensin receptor
blockers
35 (30) 36 (32) 16 (26) 18 (32) 19 (35) 18 (32)
Calcium channel
blockers
37 (32) 32 (28) 21 (34) 16 (29) 16 (29) 16 (28)
Beta-blockers 26 (22) 40 (35) 19 (31) 22 (39) 7 (13) 18 (32)
Sympatholytic agents 34 (29) 32 (28) 16 (26) 18 (32) 18 (38) 14 (25)
Lipid-lowering agents
Simvastatin 116 (100) 113 (100) 61 (100) 56 (100) 55 (100) 57 (100)
Simvastatin
monotherapy
106 (91) 98 (87) 53 (87) 47 (84) 53 (96) 51 (89)
Any lipid-lowering drug
additional to
simvastatin:
10 (9) 15 (13) 8 (13) 9 (16) 2 (4) 6 (11)
Omega-3 fatty acid 9 (8) 13 (12) 8 (13) 9 (16) 1 (2) 4 (7)
Fibrates 1 (1) 2 (2) 0 (0) 0 (0) 1 (2) 2 (4)
Ezetimibe and
omega-3 fatty acid
1 (1) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0)
Hypoglycemic therapies
Only diet 15 (13) 7 (6) 6 (10) 2 (4) 9 (16) 5 (9)
Any 101 (87) 106 (94) 55 (90) 54 (96) 46 (84) 52 (91)
Biguanides 87 (75) 86 (76) 46 (75) 41 (73) 41 (75) 45 (79)
Sulfonylureas 59 (51) 64 (57) 29 (48) 27 (48) 30 (54) 37 (54)
Thiazolidinediones 8 (7) 10 (9) 2 (3) 6 (11) 6 (11) 4 (7)
Meglitinides 2 (2) 2 (2) 1 (2) 2 (4) 1 (2) 0 (0)
Dipeptidyl peptidase-4
inhibitors
1 (1) 2 (2) 1 (2) 2 (4) 0 (0) 0 (0)
a-Glucosidase inhibitor 1 (1) 1 (1) 0 (0) 1 (2) 1 (2) 0 (0)
Oral hypoglycemic
agents alone
70 (60) 82 (73) 32 (52) 41 (73) 38 (68) 41 (72)
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stratum) and 18 were on placebo (11 in the long-term statin and 7 in the short-term statin
stratum). Differences between treatment groups considered as awhole and according to statin
stratumwere nonsignificant (P= 0.8598,P= 1.0000, andP= 0.7864 for overall, long-term, and
short-term statin, respectively). Similar findings were observed in the subgroup of patients
consenting to 24-hour BP monitoring (data not shown).
B-2. Laboratory, insulin resistance, and renal parameters
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments
(Table 2). However, in ALC and placebo treatments, HbA1c significantly increased [from 51.16
14.0 mmol/mol to 54.4 6 15.2 mmol/mol (P = 0.0007) and from 50.5 6 12.2 mmol/mol to 53.0 6
14.0 mmol/mol (P = 0.0230), respectively] whereas HOMA-IR decreased [from 3.1 (2.0 to 5.7)
to 2.6 (1.7 to 4.8) (P = 0.0251) and from 3.3 (2.1 to 5.1) to 2.9 (1.7 to 5.2) (P = 0.0267), re-
spectively] after 6 months (Table 2].
The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not
significantly different from that of placebo. After 6-month treatment with ALC all lipid
parameters remained unchanged, whereas during placebo total and HDL cholesterol sig-
nificantly increased and decreased from 155.7 6 33.7 mg/dL to 161.3 6 31.6 mg/dL (P =
0.0164) and from 44.9 6 12.0 mg/dL to 43.3 6 12.4 mg/dL (P = 0.0174), respectively.
Throughout the study neither ALC nor placebo significantly affected kidney function (in-
cluding directly measured GFR) and albuminuria (Table 2). When each stratum (long- and
short-term statin) was considered separately, metabolic and renal parameters did not sig-
nificantly differ between the ALC and placebo (Table 3). Most of the glycemic, lipid, and renal
parameters remained stable during both treatments, but HOMA-IR significantly decreased
after 6-month ALC and placebo in the short-term and in the long-term statin stratum, re-
spectively. In the short-term statin stratum HbA1c increased in ALC and placebo whereas
insulin decreased only during ALC (P , 0.01 for all parameters). Also, in the same stratum,
LDL (P , 0.05) and total cholesterol (P , 0.01) increased only when patients took placebo
(Table 3).
B-3. Safety
Overall, 6-month therapy with ALC was well tolerated. Indeed, none of the patients dis-
continued the study medication because of treatment-related side effects. Adverse events
were more frequent in the placebo than in the ALC group and most of them were mild to
moderate in nature. Serious adverse events were slightly higher in patients randomized to
Table 1. Continued
Overall (n = 229)
Previous Statin
Therapy
YES (n = 117)
Previous Statin
Therapy
NO (n = 112)
ALC
(n = 116)
Placebo
(n = 113)
ALC
(n = 61)
Placebo
(n = 56)
ALC
(n = 55)
Placebo
(n = 57)
Insulin and other
hypoglycemic
agents
22 (19) 17 (15) 16 (26) 7 (13) 6 (11) 10 (18)
Insulin alone 9 (8) 7 (6) 7 (11) 6 (11) 2 (4) 1 (2)
Data are mean (SD) or median (IQR) for continuous variables and numbers (percentages) for dichotomous variables.
aData from a subgroup of trial participants: 26, 12, and 14 patients allocated to ALC and 28, 9, and 19 patients
allocated to placebo when considered as a whole (overall) and over statin YES and statin NO stratifications,
respectively.
bData from a subgroup of trial participants: 44, 24, and 20 patients allocated to ALC and 46, 20, and 26 patients
allocated to placebo when considered as a whole (overall) and over statin YES and statin NO stratifications,
respectively.
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ALC comparedwith those to placebo. However, themost frequent serious adverse eventswere
cancer (n = 3) and cardiovascular disorders (n = 3) likely related to age, concomitant chronic
conditions, and disease progression in this high-risk population (Table 4).
3. Discussion
Treatment with ALC for 6 months on top of simvastatin did not significantly affect SBP,
insulin resistance, and lipid profile in patients with hypertension, dyslipidemia, and T2D on
stable background antihypertensive and hypoglycemic therapy. No treatment effect was
observed in the study group as a whole, as well as in the two strata on short- and long-term
statin therapy considered separately.
The pathogenesis of arterial hypertension in T2D is multifactorial and involves the
renin–angiotensin–aldosterone and endothelin-1 systems, increased oxidative stress, and
inflammatory processes. Among these pathogenetic mechanisms, impaired insulin sensi-
tivity appeared to play a pivotal role [30]. Owing to this complexity, reduction of SBP to the
normal range is seldom achievable in diabetic patients despite multidrug therapy.
Previous studies in patients with diabetes demonstrated that intravenous L-carnitine
administration could improve insulin sensitivity [12, 13]. Our pilot study also found that 2 g
per day of oral ALC improved insulin sensitivity in patientswith higher insulin resistance and
effectively decreased SBP in all nondiabetic hypertensive participants with a high cardio-
vascular risk profile [14]. However, the results from the current trial challenge the findings of
these studies.
Table 2. Effects of 6 Months of Treatment with ALC or Placebo
ALC (N = 109) Placebo (N = 110)
Baseline 6 Months Baseline 6 Months
Demographic characteristics
Weight, kg 83.0 6 14.4 83.1 6 14.8 84.6 6 15.5 84.4 6 15.6
BMI, kg/m2 30.0 6 4.8 30.1 6 5.0 30.0 6 5.1 30.0 6 5.2
Clinical characteristics
SBP, mm Hg 135.4 6 13.9 133.3 6 13.7 138.1 6 18.3 134.5 6 15.1a
DBP, mm Hg 79.9 6 6.7 78.4 6 7.5a 79.4 6 10.0 78.2 6 9.1
Mean BP, mm Hg 98.4 6 7.5 96.7 6 7.7a 98.9 6 11.1 97.0 6 9.8a
Laboratory parameters
Serum glucose 147.2 6 41.7 144.0 6 42.1 155.0 6 42.1 146.5 6 46.2
HbA1c, mmol/mol 51.1 6 14.0 54.4 6 15.2
b 50.5 6 12.2 53.0 6 14.0a
HbA1c, % 6.8 6 1.28 7.1 6 1.39
b 6.8 6 1.12 7.0 6 1.28a
Insulin, mIU/mL 8.7 [6.4–14.5] 7.8 [5.4–12.4] 8.9 [6.0–14.6] 8.5 [5.4–14.2]
HOMA-IR 3.1 [2.0–5.7] 2.6 [1.7–4.8]a 3.3 [2.1–5.1] 2.9 [1.7–5.2]a
GDR, mg/kg/minc 5.7 [4.2–8.4] 5.5 [4.9–7.2] 5.7 [4.6–7.2] 6.0 [4.9–7.6]
Total cholesterol, mg/dL 158.6 6 31.7 160.7 6 31.2 155.7 6 33.7 161.3 6 31.6a
HDL cholesterol, mg/dL 45.0 6 13.5 43.5 6 14.0 44.9 6 12.0 43.3 6 12.4a
LDL cholesterol, mg/dL 93.6 6 27.6 94.3 6 25.9 91.4 6 26.4 94.8 6 24.6
Triglycerides, mg/dL 107.0 [83.0–143.0] 107.0 [79.0–153.0] 107.0 [74.0–148.0] 111.0 [78.0–149.0]
Lipoprotein(a), mIU/mL 8.9 [3.7–35.0] 9.0 [3.0–44.2] 11.5 [3.6–28.7] 11.3 [4.3–32.5]
Kidney function parameters
Serum creatinine, mg/dL 0.93 6 0.2 0.93 6 0.2 0.94 6 0.2 0.95 6 0.2
Albuminuria, mg/min 8.0 [3.7–44.5] 8.5 [3.5–39.5] 9.0 [4.2–35.5] 11.4 [3.6–45.2]
GFR, mL/min/1.73 m2d 97.2 6 22.1 96.4 6 22.4 101.3 6 27.0 99.8 6 26.1
Data are mean (SD) or median (IQR) for continuous variables and numbers (percentages) for dichotomous variables.
For all parameters considered, we reported data from patients who completed 6 months of treatment.
aP , 0.05 vs baseline, t test or Wilcoxon rank-sum test.
bP , 0.01 vs baseline, t test or Wilcoxon rank-sum test.
cData from a subgroup of trial participants: 25 allocated to ALC and 25 patients allocated to placebo.
dData from a subgroup of trial participants: 36 allocated to ALC and 38 allocated to placebo.
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It is intriguing to speculate why ALC failed to decrease BP and/or to influence GDR
whereas significant improvements were demonstrated in patients both with and without
diabetes [12–14]. The dose of ALC was identical to that of the pilot study and other trials
reporting benefits of oral L-carnitine in different clinical settings [17–21, 23]. Moreover,
patient compliance to the study drug was close to 90%.
Nevertheless, some differences among patients’ baseline characteristics in the two studies
may justify the inconsistency of the present results. First, our study population consisted of
patients withT2D onhypoglycemic treatment comparedwith patientswithout diabetes in the
pilot study. Despite that, GDR in the present trial was slightly higher than in the pilot study
and was within the range (3.216 0.99 and 6.936 1.47 mg/kg) that was found to be associated
with a significant BP-lowering effect of ALC. Thus, the severity of insulin resistance is an
unlikely explanation for treatment failure in our present study. Second, patients with di-
abetes were older (mean age, 64.7 6 7.6 vs 44.3 6 9.3 years for the DIABASI and the pilot
study, respectively), likely implying increased resistance to the antihypertensive drugs due to
increased vascular stiffness. Third, the higher proportion of current/former smokers in this
study compared with that of the pilot study (60.4% vs 40.6%, respectively) might have
contributed to endothelial dysfunction and arterial stiffness [31], thus attenuating the effect
of ALC on SBP. Finally, recruited patients had lower SBP values as compared with those
initially assumed for sample size estimation, which might have reduced the statistical power
of the analyses.
Another crucial difference concerned statin use: all patients in the current study received
simvastatinwhereas only one subject was on statin in the pilot study. Statin therapy is known
to potentiate the effect of antihypertensive drugs [32, 33] through vasodilation, which is due to
increased nitric oxide synthase activity [34], downregulation of angiotensin II-type 1 re-
ceptors [35], and endothelin-1 production [36]. Thus, pretreatment with simvastatin might
have prevented any possible additional beneficial antihypertensive effect of ALC. Addi-
tionally, simvastatin has been shown to increase HbA1c levels and to worsen insulin sen-
sitivity [37, 38]. Actually, we observed a significant increase in HbA1c after 6 months in both
ALC and placebo groups, which was particularly evident in the short-term simvastatin
stratum. This confirms that initial treatment with simvastatin may worsen HbA1c, and that
ALC cannot counteract this detrimental effect. We could not detect the same effect in patients
on long-term statins, because HbA1c values in both ALC and placebo groups were virtually
identical throughout the study. However, even in these patients, ALC failed to improve the
glycemic profile.
Despite finding no change in the GDR, we could observe some signs of improvement in
insulin sensitivity with a significant decrease of HOMA-IR in both ALC and placebo groups at
6 months. In the short-term simvastatin stratum, ALC reduced HOMA-IR along with a
significant decrease in insulin concentration, suggesting a possible initial metabolic effect of
the study drug. However, the difference between groups was not significant, and this effect
was not observed in the group of patients on ALC in the long-term statin stratum, implying
that long-term statin therapy might have negated any beneficial effect of ALC on insulin
sensitivity.
To avoid any potential confounding effect of the duration of statin therapy on study
findings, we a priori stratified patients according to previous statin therapy YES or NO.
Moreover, we found no relationship between duration of statin therapy and treatment effect
(data not shown). Notably, the type and dose of statins used in the statin YES stratum before
the enrolment were homogeneous between study groups, with the sole exception of rosu-
vastatin, which was more frequently used in the ALC group than in the placebo group [13
patients vs 4 patients (P = 0.0001), respectively]. Thus, whether previous treatment with
rosuvastatinmight have contributed tomask themetabolic effects of ALC cannot be definitely
excluded.
The tentative lipid-lowering action of L-carnitine and ALC has been linked to increased
fatty acid b-oxidation and reduced oxidative stress due to mitochondrial dysfunction im-
provement [7, 9]. Although the results from some small trials exploring the effect of the
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combined therapy with L-carnitine and simvastatin on lipid profile in T2D were encouraging
[21–23], our results suggest that the effects of ALC on lipid profile parameters are limited
when the drug is used as an add-on statin therapy.
Consistent with earlier studies, our data confirm that treatmentwithALCwas remarkably
well tolerated with no treatment-related serious adverse event requiring treatment in-
terruption and/or patientwithdrawal. Of note, no adverse event could be directly attributed to
the study drug.
The prospective, randomized, placebo-controlled design of the trial together with the gold
standard methods used for insulin sensitivity and GFR measurements in a subgroup of
patients are themajor strength of our study.We also formally tested the effect of ALC on top of
standardized simvastatin therapy to prevent the confounding effect onmetabolic profile of the
eventual previous YES or NO statin therapy.
Finding that body weight and body mass index (BMI) were comparable at baseline and
remained unchanged in different groups and strata during the study reasonably excludes the
possibility that study results were confounded by systematic changes in diet and physical
activity introduced during the trial.
We intentionally did not standardize BP-lowering therapy during the run-in, because we
wanted to test the BP lowering effect of ALC in a context that reflects real life. Thus, the
distribution of different BP-lowering medications (and of their different combinations) in our
study population reflected the distribution in the average population of patients referred to a
diabetology unit. This enhanced the generalizability of the study findings. Alternatively,
finding that the proportion of patients using antihypertensive medications and the distri-
bution of different antihypertensive agents (and of their different combinations) were
Table 3. Effects of 6 Months of Treatment With ALC or Placebo According to Previous Treatment With
Statins (YES or NO)
Previous Statin Therapy YES (n = 112)
ALC (n = 57) Placebo (n = 55)
Baseline 6 Months Baseline 6 Months
Demographic characteristics
Weight, kg 83.2 6 14.0 83.1 6 15.0 87.2 6 17.0 86.8 6 16.8
BMI, kg/m2 30.1 6 4.4 30.2 6 4.4 31.0 6 5.5 31.0 6 5.6
Clinical characteristics
SBP, mm Hg 136.2 6 13.0 134. 0 6 13.7 138.6 6 19.3 135.8 6 16.4
DBP, mm Hg 78.8 6 6.6 77.4 6 7.4 78.8 6 10.3 78.7 6 9.9
Mean BP, mm Hg 97.9 6 7.0 96.3 6 7.5 98.7 6 11.4 97.7 6 10.7
Laboratory parameters
Serum glucose 149.1 6 45.3 145.6 6 43.9 154.2 6 44.6 143.5 6 52.9
HbA1c, mmol/mol 53.2 6 12.9 54.2 6 13.0 52.8 6 12.7 52.7 6 15.9
HbA1c, % 7.0 6 1.18 7.1 6 1.19 7.0 6 1.16 7.0 6 1.45
Insulin, mIU/mL 8.6 [6.8–14.0] 8.7 [6.1–17.8] 10.3 [6.4–16.6] 9.6 [5.7–16.7]
HOMA-IR 3.2 [2.0–5.7] 3.1 [1.9–5.8] 4.1 [2.0–5.7] 3.2 [1.4–6.6]a
GDR, mg/kg/minc 5.6 [3.9–7.8] 4.9 [3.3–6.0] 5.6 [5.1–6.5] 6.1 [5.1–7.1]
Total cholesterol, mg/dL 167.9 6 32.4 168.8 6 30.2 170.7 6 35.7 171.3 6 32.4
HDL cholesterol, mg/dL 42.7 6 10.8 41.4 6 11.7 45.6 6 12.2 43.7 6 14.0
LDL cholesterol, mg/dL 101.5 6 27.3 101.3 6 22.8 103.0 6 27.6 102.4 6 22.8
Triglycerides, mg/dL 126.0 [90.0–173.0] 135.0 [93.0–165.0] 111.0 [83.0–184.0] 125.5 [85.0–175.0]
Lipoprotein(a), mIU/mL 11.3 [4.3–36.0] 13.8 [3.9–44.2] 14.7 [3.6–30.6] 12.6 [4.1–30.6]
Kidney function parameters
Serum creatinine, mg/dL 0.92 6 0.2 0.93 6 0.2 0.95 6 0.2 0.96 6 0.2
Albuminuria, mg/min 7.8 [3.7–41.8] 8.1 [3.5–29.1] 17.1 [4.2–55.2] 12.2 [3.8–49.9]
GFR, mL/min/1.73 m2d 99.3 6 20.4 96.6 6 20.4 99.3 6 29.5 99.6 6 27.8
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comparable between groups can be taken to suggest that data were very unlikely confounded
by concomitant BP-lowering therapy, even if it was not standardized.
Although concomitant medication changes were not recommended throughout the study
period, adjustments in antihypertensive and antidiabetic treatments were conceded in se-
lected cases to avoid acute clinical complications during the trial. However, the adherence
pattern to chronic treatments was stable and the differences in antihypertensive and an-
tidiabetic medication changes during the study period between treatment groups and strata
were not statistically significant.
A potential limitation of this study was the unavailability of baseline and follow-up
measurements of plasma carnitine levels. However, it is well known that plasma carni-
tine is low in patients with T2D, especially in the presence of dyslipidemia or microvascular
complications [39]. This evidence strengthens the rationale of ALC use in this cohort. Al-
ternatively, wewanted to test the possible BP-lowering effect of ALC above and beyond that of
available medications in everyday clinical practice, a context in which serum carnitine level
is a parameter that cannot be considered routinely for selection of potential candidates for
treatment. In the case of encouraging findings, the role of serum carnitine as a tool to identify
patients who may benefit the most from ALC therapy could have been evaluated in further
studies.
Table 3. Continued
Previous Statin Therapy NO (n=107)
ALC (n = 52) Placebo (n = 55)
Baseline 6 Months Baseline 6 Months
Demographic characteristics
Weight, kg 82.7 6 15.0 83.1 6 15.9 82.1 6 13.3 82.0 6 14.0
BMI, kg/m2 29.9 6 5.3 30.0 6 5.6 29.1 6 4.6 29.1 6 4.7
Clinical characteristics
SBP, mm Hg 134.6 6 14.9 132.6 6 13.9 137.6 6 17.4 133.2 6 13.6a
DBP, mm Hg 81.2 6 6.6 79.5 6 7.5 79.9 6 9.7 77.8 6 8.3
Mean BP, mm Hg 99.6 6 7.3 97.2 6 8.0 99.1 6 10.9 96.3 6 8.8a
Laboratory parameters
Serum glucose 145.1 6 37.7 142.3 6 40.4 155.7 6 39.8 149.5 6 38.8
HbA1c, mmol/mol 48.9 6 14.9 54.7 6 17.3
b 48.2 6 11.5 53.3 6 12.0b
HbA1c, % 6.6 6 1.36 7.2 6 1.58
b 6.6 6 1.05 7.0 6 1.10b
Insulin, mIU/mL 9.1 [5.7–14.5] 6.8 [4.5–11.4]b 7.9 [5.9–12.0] 8.0 [5.4–10.6]
HOMA-IR 3.0 [1.8–5.8] 2.2 [1.5–4.1]b 2.9 [2.1– 4.7] 2.8 [1.8–4.7]
GDR, mg/kg/minc 6.3 [4.3–8.4] 5.7 [5.5–8.7] 5.9 [4.2–7.9] 6.0 [4.9–7.7]
Total cholesterol, mg/dL 148.4 6 27.8 151.8 6 30.4 141.0 6 24.0 151.3 6 27.6b
HDL cholesterol, mg/dL 47.5 6 15.6 45.8 6 15.8 44.2 6 11.9 43.0 6 10.8
LDL cholesterol, mg/dL 84.9 6 25.4 86.5 6 27.0 80.0 6 19.3 87.3 6 24.0b
Triglycerides, mg/dL 97.0 [63.0–119.0] 85.5 [65.0–116.5] 101.0 [64.0–126.0] 105.0 [69.0–141.0]
Lipoprotein(a), mIU/mL 6.1 [3.2–34.7] 7.0 [2.4–44.2] 9.4 [3.5–28.6] 10.8 [4.5–33.2]
Kidney function parameters
Serum creatinine, mg/dL 0.94 6 0.2 0.93 6 0.2 0.93 6 0.2 0.93 6 0.2
Albuminuria, mg/min 10.4 [3.7–66.2] 8.8 [3.5–54.5] 5.7 [3.6–31.2] 8.4 [3.1–4.3]
GFR, mL/min/1.73 m2d 94.4 6 24.9 96.1 6 25.7 102.8 6 25.6 99.9 6 25.4
Data are mean (SD) or median (IQR) for continuous variables and numbers (percentages) for dichotomous variables.
For all parameters considered, we reported data from patients who completed 6 months of treatment.
aP , 0.05 vs baseline, t test or Wilcoxon rank-sum test.
bP , 0.01 vs baseline, t test or Wilcoxon rank-sum test.
cData from a subgroup of trial participants: 11 and 13 patients allocated to ALC and 8 and 17 patients allocated to
placebo when stratifications to statin YES and statin NO were considered, respectively.
dData from a subgroup of trial participants: 23 and 15 patients allocated to ALC and 17 and 22 patients allocated to
placebo when stratifications to statin YES and statin NO were considered, respectively.
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4. Conclusion
Oral ALC does not improve either SBP control or the lipid and glycemic profile in diabetic
hypertensive patients on stable statin therapy. We hypothesized that the possible hypo-
tensive and hypolipidemic effect of ALC is blunted by statin use. It is worth exploring this
objective in patients with and without diabetes and with hypertension who do not require
treatment with statins.
Appendix 1
DIABASI Study Organization: Members of the DIABASI Study Organization were as follows:
Principal Investigator—N. Perico [IRCCS -Mario Negri Institute for Pharmacological Research,
Clinical Research Center for Rare Diseases “Aldo e Cele Dacco`”, Ranica (Bergamo), Italy];
Scientific Study Coordinators—P. Ruggenenti, G. Remuzzi (IRCCS - Mario Negri Institute for
Pharmacological Research, Clinical Research Center for Rare Diseases “Aldo e Cele Dacco`”);
Coordinating Center—IRCCS - Mario Negri Institute for Pharmacological Research, Clinical
Research Center for Rare Diseases “Aldo e Cele Dacco`”; Participating Centers—N. Perico,
S. Rota, B. Ruggiero, A. Panozo, M. Abbate, B. Pahari, K. Courville, S. Prandini, V. Lecchi,
G.Gherardi (IRCCS-MarioNegri Institute forPharmacologicalResearch,ClinicalResearchCenter
for RareDiseases “Aldo eCeleDacco`”); R. Trevisan, A. Corsi, A.R.Dodesini, R. Rota, C. Aparicio
(UOMalattieEndrocrine eDiabetologia–ASSTPapaGiovanniXXIII,Bergamo, Italy); A.Bossi,
A. Parvanova, I. Iliev, S. Yakymchuk [UOCMalattie Endocrine eCentro Regionale per il Diabete
Mellito–ASST Bergamo Ovest–Ospedale Treviglio-Caravaggio, Treviglio (Bergamo), Italy];
Table 4. Adverse Events in the Study as Whole and in the Two Treatment Groups
Overall ALC Placebo
Total 193 95 98
Serious adverse events
Total 12 7 5
Any cancer 3 2 1
Metastatic squamous cell carcinoma of the
hypopharynx
1 1 0
Monofocal hepatocellular carcinoma 1 1 0
Melanoma 1 0 1
Any cardiovascular event 3 2 1
Dilatative and hypocynetic cardiomyopathy 1 1 0
Ischemic cardiopathy 1 1 0
Angina pectoris 1 0 1
Other events 6 3 3
Respiratory distress 1 1 0
Posttraumatic subarachnoid hemorrhage 1 1 0
Adductor magnus muscle strain 1 1 0
Shoulder tendinous lesion 1 0 1
Nonserious adverse events (system organ
classification)
Total 181 88 93
Musculoskeletal disorders and trauma 36 21 15
Gastrointestinal and hepatobiliary disorders 32 14 18
Respiratory and thoracic disorders 19 11 8
Cardiac and vascular disorders 18 8 10
Metabolism, nutritional, and endocrinology
disorders
18 6 12
Laboratory abnormalities 15 9 6
Ocular, ear, and labyrinth disorders 13 3 10
Dermatology and allergic disorders 11 5 6
Nervous system and psychiatric disorders 7 3 4
Urologic disorders 6 4 2
General disorders 6 4 2
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A.Bossi, I. Petrov Iliev,A.Parvanova,V.Lecchi [UOCMalattieEndocrine eCentroRegionaleper il
Diabete Mellito–ASST Bergamo Ovest–Ospedale SS. Trinita`, Romano di Lombardia, (Bergamo),
Italy]; A. Belviso, M. Trillini, S. Yakymchuk [ASST Bergamo Ovest–Poliambulatorio Extra
Ospedaliero Brembate Sopra, (Bergamo), Italy]; Monitoring and Drug Distribution—N. Rubis,
W. Calini, O. Diadei (IRCCS - Mario Negri Institute for Pharmacological Research, Clinical
Research Center for Rare Diseases “Aldo e Cele Dacco`”); Database and Data Validation—
S. Carminati, D.Martinetti (IRCCS -MarioNegri Institute for Pharmacological Research, Clinical
Research Center for Rare Diseases “Aldo e Cele Dacco`”); Data Analysis and Randomization—
A. Perna, G. A. Giuliano, I. Foiadelli, G. Stanzione, - (IRCCS - Mario Negri Institute for Phar-
macological Research, ClinicalResearchCenter forRareDiseases “Aldo eCeleDacco`”); Laboratory
Measurements—F.Gaspari, F. Carrara, S. Ferrari, N. Stucchi, A. Cannata (IRCCS -MarioNegri
Institute for Pharmacological Research, Clinical Research Center for Rare Diseases “Aldo e Cele
Dacco`”); Regulatory Affairs—P. Boccardo, S. Peracchi (IRCCS - Mario Negri Institute for
Pharmacological Research, Clinical Research Center for Rare Diseases “Aldo e Cele Dacco`”).
Appendix 2
Scientific Writing Academy 2015—Tutor: David G. Warnock, MD, Department of Medicine,
University of Alabama at Birmingham, Birmingham, Alabama. Participants: Matias Trillini,
MD, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy; Aneliya
Parvanova, MD, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy;
Sreejith Parameswaran, MD, Jawaharlal Institute of Postgraduate Medical Education and
Research, India; Jonathan S. Cha´vez-I~niguez, MD, Hospital Civil de Guadalajara “Fray
Antonio Alcalde,” Servicio de Nefrologı´a, Guadalajara, Jalisco, Mexico; Fahrudin Masnic,
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